Brought to you by 
Gilead pays $11.2bn for HCV company Pharmasset
18 Jan 2012
Executive Summary
In a bold move that gives it a stronger foothold in the competitive hepatitis C therapeutics market, Gilead Sciences Inc. paid $137 per share (a 96% premium), or $11.2bn, to acquire public antivirals biotech Pharmasset Inc. The purchase price is the highest ever paid for a clinical-stage biotech.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Intra-Biotech Deal
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com